6533b85afe1ef96bd12b9f9c
RESEARCH PRODUCT
Maintenance therapy with avelumab (MSB0010718C; anti-PD-L1) vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric cancer: The phase 3 JAVELIN Gastric 100 trial.
Markus MoehlerJulien TaiebJenny ZhangNarikazu BokuJean-marie CuillerotHuiling XiongJayne S. Gurtlersubject
0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybiologybusiness.industryLocally advancedbiology.organism_classificationAvelumab03 medical and health sciences030104 developmental biology0302 clinical medicineImmune systemOncologyMaintenance therapyJavelin030220 oncology & carcinogenesisInternal medicinemedicineIn patientFirst line chemotherapyReceptorbusinessmedicine.drugdescription
TPS4134Background: Programmed death-1 receptor ligand (PD-L1) is a key therapeutic target in the reactivation of the immune response against multiple cancers. Avelumab* is a fully human anti-PD-L1 ...
year | journal | country | edition | language |
---|---|---|---|---|
2016-05-20 | Journal of Clinical Oncology |